Phase III, randomized, double-blind clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer, followed by adjuvant atezolizumab or placebo. (GEPARDOUZE)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: GERMAN BREAST GBG FORSCHUNGSGESELLSCHAFT GMBH
- Phase: III
- Execution start: 23/07/2020
- End of execution: 30/09/2024
- IP: ISABEL BLANCAS LOPEZ-BARAJAS